Table 1.
Clinicopathologic characteristics of ovarian cancer patients included in this study.
| ID | Tumor type |
BRCA status |
Date primary diagnosis |
Stage primary disease |
Neoadjuvant chemotherapy |
Cycles platinum- based chemotherapy (n) |
Date disease progression/ distant relapse |
Primary refractory/ resistant disease |
Secondary refractory/ resistant disease |
Date blood draw |
Disease location at blood draw |
Time follow- up (years) |
Follow- up |
cfDNA (ng) per ml plasma |
Fraction ctDNA in cfDNA (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCT1 | HGSOC | BRCA1 | February 2008 | Stage III | No | 6 | May 2010 | Resistant | August 2013 | Intra | 8 | DOD | 27.9 | NA | |
| OCT2 | HGSOC | BRCA2 | February 2011 | Stage III | No | 6 | May 2012 | Refractory | August 2013 | Intra and extra | 3 | DOD | 20.4 | 32.74 | |
| OCT3 | HGSOC | BRCA2 | July 2010 | Stage IV | No | 6 | July 2012 | Resistant | August 2013 | NED | 6 | AWD | 16.3 | 0 | |
| OCT5 | HGSOC | BRCA1 | July 2012 | Stage III | No | 6 | May 2013 | Resistant | Refractory | September 2013 | NED | 4 | AWD | 12.0 | NA |
| OCT6 | HGSOC | BRCA1 | May 2010 | Stage IV | No | 6 | July 2011 | Refractory | September 2013 | Intra | 4 | DOD | 7.6 | 2.49 | |
| OCT7 | HGSOC | BRCA2 | May 2008 | Stage III | No | 6 | June 2009 | Refractory | September 2013 | Intra | 8 | DOD | 6.2 | 0.32 | |
| OCT8 | HGSOC | BRCA2 | July 2006 | Stage IV | No | 6 | July 2007 | Refractory | September 2013 | Intra and extra | 8 | DOD | 5.9 | 1.60 | |
| OCT9 | HGSOC | BRCA1 | April 2011 | Stage IV | No | 6 | August 2012 | Refractory | October 2013 | Intra and extra | 3 | DOD | 12.0 | 0.08 | |
| OCT10 | HGSOC | BRCA1 | January 2012 | Stage IV | Yes (4 cycles) | 3 | January 2013 | Resistant | No | October 2013 | Intra | 4 | NED | 4.8 | 0.26 |
| OCT11 | HGSOC | BRCA2 | June 2006 | Stage IV | No | 7 | October 2008 | Resistant | December 2013 | Intra and extra | 9 | DOD | 11.6 | 10.30 | |
| OCT12 | HGSOC | BRCA2 | June 2007 | Stage III | No | 6 | July 2010 | Refractory | June 2014 | Intra | 8 | DOD | 10.8 | 0.05 | |
| OCT13 | HGSOC | BRCA1 | December 2007 | Stage II | No | 6 | January 2011 | Refractory | June 2014 | Intra | 7 | DOD | 5.5 | 0.14 | |
| OCT14 | HGSOC | BRCA1 | January 2012 | Stage III | No | 6 | June 2013 | Resistant | June 2014 | Intra | 4 | DOD | 24.3 | 0.08 | |
| OCT15 | HGSOC | BRCA1 | August 2012 | Stage IV | Yes (3 cycles) | 3 | October 2013 | Resistant | August 2014 | Intra | 3 | DOD | 32.4 | 0.31 | |
| OCT17 | HGSOC | BRCA1 | August 2008 | Stage IV | No | 6 | January 2010 | Refractory | September 2014 | Intra and extra | 8 | DOD | 17.4 | 4.48 | |
| OCT18 | HGSOC | BRCA2 | May 1996 | Stage II | No | 6 | December 2004 | Resistant | October 2014 | Intra | 19 | DOD | 11.4 | 5.32 | |
| OCT19 | HGSOC | BRCA1 | September 2010 | Stage III | No | 6 | December 2011 | Refractory | December 2014 | Intra | 4 | DOD | 30 | 0.61 | |
| OCT20 | HGSOC | BRCA1 | June 2008 | Stage III | No | 6 | February 2010 | Refractory | December 2014 | Intra | 7 | DOD | 32.4 | 0.12 | |
| OCT21 | Endometrioid (serous components) | BRCA1 | June 2008 | Stage III | No | 14 | December 2010 | Refractory | March 2015 | Intra and extra | 7 | DOD | 15 | 0.24 |
AWD, alive with disease; DOD, dead of disease; HGSOC, high grade serous ovarian cancer; intra, Intra-abdominal; Intra and extra, intra- and extra-abdominal; MAF, mutant allele fraction; NA, not assessable due to the lack of a somatic mutation bioinformatically inferred as clonal in the tumor sample; hence, the fraction of ctDNA in cfDNA could not be calculated; NED, no evidence of disease; ND, not detectable.